Role of Efflux Pumps and Mutations in Genes for Topoisomerases II and IV in Fluoroquinolone-Resistant Pseudomonas aeruginosa Strains

Microbial Drug Resistance

Volumn 9, Issue 4, 2003, Pages 323-328

  Oh, Herin ^a   Stenhoff, Jonas ^a   Jalal, Shah ^a   Wretlind, Bengt ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; GENE PRODUCT; MESSENGER RNA; PROTEIN MEXB; PROTEIN MEXD; PROTEIN MEXF; PROTEIN MEXY; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN TRANSPORT; PSEUDOMONAS AERUGINOSA; STRAIN DIFFERENCE;

ANTI-INFECTIVE AGENTS; DNA TOPOISOMERASE IV; DNA TOPOISOMERASES, TYPE II, BACTERIAL; DNA, BACTERIAL; DNA, COMPLEMENTARY; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; GENES, BACTERIAL; PSEUDOMONAS AERUGINOSA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, BACTERIAL; RNA, MESSENGER;

PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

EID: 0842307683     PISSN: 10766294     EISSN: None     Source Type: Journal    
DOI: 10.1089/107662903322762743     Document Type: Article

References (30)

1. Aires, J.R., T. Köhler, H. Nikaido, and P. Plesiat. 1999. Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob. Agents Chemother. 43:2624-2628.
2. Akasaka, T., M. Tanaka, A. Yamaguchi, and K. Sato. 2001. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob. Agents Chemother. 45:2263-2268.
3. Bachoual, R., J. Tankovic, and C.J. Soussy. 1998. Analysis of the mutations involved in fluoroquinolone resistance of in vivo and in vitro mutants of Escherichia coli. Microb. Drug Resist. 4:271-276.
4. Breines, D.M., Ouabdesselam, S., Ng, E.Y., Tankovic, J., Shah, S., Soussy, C.J., and Hooper, D.C. 1997. Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV. Antimicrob. Agents Chemother. 41:175-179.
5. Bridges, B.A. 1997. Microbial genetics. Hypermutation under stress. Nature 387:557-558.
6. Drlica, K., and Zhao, X. 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Molec. Biol. Rev. 61:377-392.
7. Fournier, B., and Hooper, D. C. 1998. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity. Antimicrob. Agents Chemother. 42:121-128.
8. Gensberg, K., Y.F. Jin, and L.J. Piddock. 1995. A novel gyrB mutation in a fluoroquinolone-resistant clinical isolate of Salmonella typhimurium. FEMS Microbiol. Lett. 132:57-60.
9. Heisig, P. 1996. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob. Agents Chemother. 40:879-885.
10. Jalal, S., Amin, N.E, Gotoh, N., and Wretlind, B. 6-30-1999. Mutations to quinolone resistance in Pseudomonas aeruginosa and Enterococcus faecium. Drugs 58(Suppl. 2):119-120.
11. Jalal, S., Ciofu, O., Hoiby, N., Gotoh, N., and Wretlind, B. 2000. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob. Agents Chemother. 44:710-712.
12. Jalal, S., and B. Wretlind. 1998. Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa. Microb. Drug Resist. 4:257-261.
13. Jorgensen, J.H., L.M. Weigel, M.J. Ferraro, J.M. Swenson, and F.C. Tenover. 1999. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci. Antimicrob. Agents Chemother. 43:329-334.
14. Kiewitz, C. and B. Tummler. 2000. Sequence diversity of Pseudomonas aeruginosa: impact on population structure and genome evolution. J. Bacteriol. 182:3125-3135.
15. Köhler, T., S.F. Epp, L.K. Curty, and J.C. Pechère. 1999. Characterization of MexT, the regulator of the MexE-MexF-OprN multidrug efflux system of Pseudomonas aeruginosa. J. Bacteriol. 181:6300-6305.
16. Li, Y., T. Mima, Y. Komori, Y. Morita, T. Kuroda, T. Mizushima, and T. Tsuchiya. 2003. A new member of the tripartite multidrug efflux pumps, MexVW-OprM, in Pseudomonas aeruginosa. J. Antimicrob. Chemother. 52:572-575.
17. Lomovskaya, O., M.S. Warren, A. Lee, J. Galazzo, R. Fronko, M. Lee, J. Blais, D. Cho, S. Chamberland, T. Renau, R. Leger, S. Hecker, W. Watkins, K. Hoshino, H. Ishida, and V.J. Lee. 2001. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob. Agents Chemother. 45:105-116.
18. Martinez-Martinez, L., A. Pascual, and G.A. Jacoby. 1998. Quinolone resistance from a transferable plasmid. Lancet 351:797-799.
19. Masuda, N., E. Sakagawa, S. Ohya, N. Gotoh, H. Tsujimoto, and T. Nishino. 2000. Contribution of the MexX-MexY-OprM efflux system to intrinsic resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44:2242-2246.
20. Mine, T., Y. Morita, A. Kataoka, T. Mizushima, and T. Tsuchiya. 1999. Expression in Escherichia coli of a new multidrug efflux pump, MexXY, from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 43:415-417.
21. Mouneimne, H., J. Robert, V. Jarlier, and E. Cambau. 1999. Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 43:62-66.
22. Nakano, M., T. Deguchi, T. Kawamura, M. Yasuda, M. Kimura, Y. Okano, and Y. Kawada. 1997. Mutations in the gyrA and parC genes in fluoroquinolone-resistant clinical isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 41:2289-2291.
23. Oliver, A., R. Canton, P. Campo, F. Baquero, and J. Blazquez. 2000. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288:1251-1253.
24. Perichon, B., J. Tankovic, and P. Courvalin. 1997. Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:1166-1167.
25. Pitcher, D.G., N.A. Saunders, and R.J. Owen. 1989. Rapid extraction of bacterial genomic DNA with guanidium thiocyanate. Lett. Appl. Microbiol. 8:151-156.
26. Poole, K. 2001. Multidrug resistance in Gram-negative bacteria. Curr. Opin. Microbiol. 4:500-508.
27. Poole, K., N. Gotoh, H. Tsujimoto, Q. Zhao, A. Wada, T. Yamasaki, S. Neshat, J. Yamagishi, X.Z. Li, and T. Nishino. 1996. Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug-resistant strains of Pseudomonas aeruginosa. Mol. Microbiol. 21:713-724.
28. Poole, K., K. Tetro, Q. Zhao, S. Neshat, D.E. Heinrichs, and N. Bianco. 1996. Expression of the multidrug resistance operon mexA-mexB-oprM in Pseudomonas aeruginosa: mexR encodes a regulator of operon expression. Antimicrob. Agents Chemother. 40:2021-2028.
29. Ringertz, S., B. Olsson-Liljequist, G. Kahlmeter, and G. Kronvall. 1997. Antimicrobial susceptibility testing in Sweden. 11. Species-related zone diameter breakpoints to avoid interpretive errors and guard against unrecognized evolution of resistance. Scand. J. Infect. Dis. (Suppl.) 105:8-12.
30. Stein, D. C., R. J. Danaher, and T.M. Cook. 1991. Characterization of a gyrB mutation responsible for low-level nalidixic acid resistance in Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 35:622-626.